**METHODOLOGY**

*Plasmodium berghei* bio-burden correlates with parasite lactate dehydrogenase: application to murine *Plasmodium* diagnostics

Sai Lata De¹, Danielle I. Stanisic¹, Fabian Rivera², Michael R. Batzloff¹, Christian Engwerda² and Michael F. Good¹*

**Abstract**

**Background:** The spectrum of techniques to detect malaria parasites in whole blood is limited to measuring parasites in circulation. One approach that is currently used to enumerate total parasite bio-burden involves the use of bio-luminescent parasites. As an alternative approach, this study describes the use of a commercial ELISA human parasite lactate dehydrogenase (pLDH) detection kit to estimate total parasite bio-burden in murine malaria models.

**Methods:** The cross reactivity of pLDH in a commercial human malaria pLDH diagnostic kit was established in different components of blood for different murine malaria models. The use of pLDH as a measure of parasite bio-burden was evaluated by examining pLDH in relation to peripheral blood parasitaemia as determined by microscopy and calculating total parasite bio-burden using a bio-luminescent *Plasmodium berghei* ANKA luciferase parasite.

**Results:** The pLDH antigen was detected in all four murine *Plasmodium* species and in all components of *Plasmodium*-infected blood. A significant correlation ($r = 0.6922$, P value $<0.0001$) was observed between total parasite bio-burden, measured as log average radiance, and concentration of pLDH units.

**Conclusions:** This high throughput assay is a suitable measure of total parasite bio-burden in murine malaria infections. Unlike existing methods, it permits the estimation of both circulating and sequestered parasites, allowing a more accurate assessment of parasite bio-burden.

**Keywords:** Malaria, pLDH, Murine *Plasmodium*, Parasite bio-burden

**Background**

Malaria continues to be a leading cause of mortality in endemic countries, despite control and eradication initiatives, such as the use of insecticide-treated bed nets and anti-malaria drug treatment [1]. Clinical disease typically presents as fever, chills, severe headache, and vomiting, and requires a prompt diagnosis followed by effective treatment to ensure resolution of the infection. Importantly, disease outcomes are directly correlated with total parasite burden [2]. In rodent malaria models, Giemsa-stained blood films (the gold-standard microscopy technique) [3, 4], PCR [5], flow cytometry [6, 7], fluorescent [8, 9] or DNA/RNA [10–12] markers and radioisotope labelling [11] have been used to measure parasitaemia in vivo preclinical efficacy studies for anti-malaria drugs and vaccine candidates. However, these approaches are limited to detecting circulating parasites and do not account for sequestered parasites, which is important for determining total parasite bio-burden. Bio-luminescence imaging, using transgenic parasite that express the firefly luciferase reporter protein, has been used not only to measure parasite growth in vivo and in vitro [10], but also to visualize in vivo the parasite sequestration in deep tissues [13–16].

Various assays using specific antibodies to parasite antigens have been employed [17–24]. Immunochromatographic assays, which utilize monoclonal antibodies against specific *Plasmodium* enzymes, are under development. The most promising antigens explored so far include: histidine rich protein-2 (HRP-2) [25],
parasite-specific lactate dehydrogenase (pLDH) [18, 19, 26–28], and aldolase [29, 30]. These enzymes are involved in metabolic pathways essential for the growth and survival of *Plasmodium* parasites [29].

The enzyme pLDH is a soluble, energy-producing enzyme that is involved in the last step of the glycolytic pathway [29]. As the red blood cells do not have functional mitochondria and the parasites have minimum oxygen uptake for the citric acid cycle [31], it is highly dependent on anaerobic glucose metabolism [32, 33]. pLDH is produced by both asexual blood-stage parasites as well as the sexual stages, with a larger quantity of pLDH being produced during the asexual stage [29]. pLDH antigen is preferable as a diagnostic marker over other antigens such as HRP-2, which is limited to *Plasmodium falciparum* only [34]. Moreover, some *P. falciparum* strains have a deletion in the HRP-2 gene, resulting in false negative tests [35]. Unlike HRP-2, pLDH does not persist in the blood [36, 37] and is cleared immediately post-active infection [18–20, 22, 38, 39], thus making pLDH an ideal marker to estimate parasite bio-burden at the time of the assay.

Previously, monoclonal antibodies specific for pLDH have been used to determine the sensitivity of *Plasmodium berghei* to anti-malarial drugs in vitro [40]. A chromogenic pLDH assay has also been employed to enumerate the parasites in the blood of mice challenged with *Plasmodium yoelii* 17XNL post vaccination with MSP1-19 [41]. However, none of these approaches was compared to an established assay to quantify and validate total parasite bio-burden.

The pLDH amino acid sequence has a 90 % sequence identity amongst all human *Plasmodium* species [33, 42]. For human parasites, monoclonal antibodies against the shared common epitopes can be used to detect all species [43, 44]. Genetic conservation and variation of pLDH across different human and rodent species and strains of *Plasmodium* was reported by Talman et al. [45]. Nucleotide BLAST analysis using 951 nucleotides of the *P. falciparum* 3D7 (PfLDH) gene coding sequence [Accession ID XM_001349953.1] as the reference revealed the following per cent identity in different species of murine *Plasmodium*: 86 % identity with *P. yoelii* 17XNL [Accession ID XM_719008.1]; 85 % with *Plasmodium chabaudi* chabaudi [Accession ID XM_740087.1]; 85 % with *P. berghei* ANKA [Accession ID XM_674309.1]; and 83 % with *Plasmodium vinсeki* [Accession ID XM_008624100.1]. The high degree of sequence similarity could potentially be exploited for use in diagnostics for rodent malaria parasites (Table 1).

This study investigated the use of a commercial human *Plasmodium* pLDH ELISA diagnostic kit for detecting pLDH antigen as a measure of parasite bio-burden during murine malaria infections. This assay could be established as an alternative approach to measure parasite bio-burden in efficacy studies.

**Methods**

**Mice and ethics statement**

Female BALB/c mice aged 4–6 weeks were purchased from the Animal Resource Centre (ARC) (Canning Vale, Perth, Australia) and maintained under appropriate ARC and Griffith University conditions. This study was carried out in strict accordance with the National Health and Medical Research Council of Australia guidelines, as detailed in the document, *Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 8th ed* [46]. The Griffith University Animal Ethics Committee (GLY/05/12/AEC) and the QIMR Berghofer Medical Research Institute Ethics Committee (A02633M) approved the relevant animal procedures and protocols.

**Parasites and infections**

Cloned lines of *P. chabaudi* AS, *P. yoelii* 17XNL, *P. yoelii* YM, *P. berghei* and *P. vinсeki* were used (provided by Richard Carter, University of Edinburgh, UK). Stabiliates were maintained by intra-venous (IV) and intra-peritoneal (IP) passaging of 10⁶ parasitized red blood cells (pRBC) into naïve BALB/c mice. *Plasmodium berghei* ANKA luc lines (provided by Chris Janse, Leiden University Medical Centre, The Netherlands) were used in the bio-luminescent experiments for in vivo imaging after one in vivo passage in mice.

**Evaluation of parasitaemia by microscopy**

Thin blood smears were prepared, air dried, fixed in methanol and stained with Giemsa. Slides were examined using bright field microscopy and counts were performed with 100× magnification. For negative or low parasitaemia films (<1 %), at least 20 fields on the slide were counted. For high parasitaemia, at least 500 RBCs were counted. Percent parasitaemia was calculated as the number of pRBCs multiplied by 100 divided by the number of total RBCs.

**Assessment of pLDH antigen production in murine malaria models**

Qualitative and quantitative levels of pLDH antigens in BALB/c mice infected with *P. chabaudi* AS, *P. yoelii* 17XNL, *P. yoelii* YM, *P. berghei* ANKA, and *P. vinсeki* were determined using the pLDH SD Malaria Antigen ELISA kit (Standard Diagnostics), a sandwich ELISA for the qualitative detection of human *Plasmodium* pLDH. For quantitative assessment, blood was collected on the following days for each of the rodent malaria parasites: *P. chabaudi* AS: Day 7 (29 %), *P. berghei* ANKA: Day 4...
Table 1. pLDH protein sequence alignment analysis of different species of murine Plasmodium

| pLDH sequence alignment using Clustal Omega |
|-------------------------------------------|
|                                | 1   | 60 |
| *P. falciparum* 3D7 | MAPKAKIVLVGGMIGGVMATLIVQKNGLGV-VMFDIVKMPKALDSTHTVNYMAYSNCNK |
| *P. vinckei*       | VTGSNYDDLKADVIVTAGFTKAPKGD-KEWRDQLIPLKKMREGGKIKNNCPNA |
| *P. chabaudi*      | VSQNTYDDLKADVIVTAGFTKAPKGD-KEWRDQLIPLKKMREGGKIKNNCPNA |
| *P. falciparum* 3D7 | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. vinckei*       | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. chabaudi*      | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. falciparum* 3D7 | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. vinckei*       | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. chabaudi*      | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. falciparum* 3D7 | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. vinckei*       | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. chabaudi*      | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. falciparum* 3D7 | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. vinckei*       | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. chabaudi*      | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. falciparum* 3D7 | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. vinckei*       | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |
| *P. chabaudi*      | FIIVTVNDVMQLQQSGQKPFNKG1GLG-GVLDTSRLKYISQKLNCPRDNVAHIVG |

(34 %), *P. vinckei*: Day 4 (32 %), and *P. yoelii* YM: Day 5 (24 %). Recombinant pLDH supplied as the positive control in the kit was used to generate a standard curve dilution series with a starting concentration of 1320 ng/mL in PBS or naïve mouse blood. Fifty microlitres of the samples (negative and positive control, standard curve and test samples) were tested in triplicate and the manufacturer’s instructions were followed. Plates were read on an xMark microplate spectrophotometer (Biorad) at 450 nm, with a reference wavelength of 620 nm. The reading was completed within 30 min of the stop solution being added. The linear range was then logistically plotted to generate a linear equation to quantify levels of pLDH units in test samples. Positive wells were used to measure the concentration of pLDH unit, with the cut-off for positivity calculated as the mean + three standard deviations of the wells containing naïve mouse blood or PBS alone. The mean optical densities (ODs) were calculated for standards and used to plot a standard curve OD vs ng/mL recombinant pLDH antigen. The concentration of pLDH units in the samples was calculated from the optical density reading from the linear range of the standard curve (as in Fig. 2) such that 1 unit/mL in the test sample was equivalent to 1 ng/mL.

Visualization and quantification of luciferase activity in mice infected with *Plasmodium berghei* ANKA luciferase

Luciferase activity in *P. berghei* ANKA luciferase infected mice was visualized using an intensified-charge-coupled device (I-CCD) video camera of the in vivo Imaging System (IVIS 100, Xenogen) [8]. Mice were anesthetized using the isofluorane anaesthesia system (XGI-8, Xenogen). Following this, mice were injected IP with β-luciferin dissolved in PBS (100 mg/kg of body weight; Synchem, Kassel, Germany) and measurements were performed within 5 min of injection. Bio-luminescence imaging was acquired with an exposure time of 60 s. Imaging data
were analysed using the living image (Xenogen) program. In asynchronous infections, measurements were performed on different days at the same time.

**Statistical analysis**

Graphical and statistical analysis was performed using GraphPad Prism 6. All the datasets are presented as mean ± SE, unless stated otherwise. Non-linear standard curves were generated and the linear part of the curve was used for re-plotting three or more points in logarithmic scale. Logarithmic and arithmetic curves were both used for fitting a trend-line and obtaining an equation, which was used to calculate the concentration of pLDH units from the mean absorbance, for each test sample as described above. The limit of detection (LOD) was calculated as the lowest value in the dilution series that was significantly different from the negative control values. An ANOVA was performed to estimate the LOD. One-way ANOVA was used for the analyses presented in Figs. 1a and 2a. b. Correlation analyses between concentration of pLDH units, parasitaemia and log average radianc were determined using Pearson’s correlation analysis. A Pearson $r$ value greater than 0.6 was considered as a strong correlation and shown in the appropriate figures. $P$ values less than 0.05 were deemed significant for all statistical analyses.

**Results**

**Qualitative detection of pLDH in different blood components in mice infected with Plasmodium chabaudi AS**

Due to the sequence similarity between the mouse and human *Plasmodium* LDH genes [45], this study utilized the human *Plasmodium* pLDH ELISA kit to assess its ability to detect murine *Plasmodium* pLDH. In a pilot study, pLDH was detected in both whole blood and serum obtained from a *P. chabaudi* AS infected mouse on day 7 post infection at 31% parasitaemia ($P$ value
Whole blood and serum from both the naïve mouse and a mouse infected with *P. chabaudi* AS and drug cured (100 µL of malarone orally for 5 days), did not have significant detectable pLDH units (Fig. 1a).

**Generation of standard curves using recombinant pLDH**

Standard curves were generated for quantitative assessment of pLDH units in infected mice. Using the positive control (rec pLDH) from the commercial ELISA kit, serial dilutions were performed in both PBS and naïve mouse blood to establish standard curves. A representative standard curve from which the linear range was derived is shown in Fig. 1b. The linear range was approximately between 1.18 and 52.8 ng/mL.

**Quantification of pLDH units in different species of murine *Plasmodium***

It was next established if this assay could be used to quantify pLDH units in the whole blood from mice infected with each of the four species of murine malaria. pLDH was detectable in whole blood obtained from mice infected with each of the rodent *Plasmodium* species (Fig. 2a). Despite a similar parasitaemia (24–34 %), pLDH units were significantly lower in mice infected with *P. vinckei* compared to the mice infected with *P. chabaudi* AS, *P. berghei* ANKA and *P. yoelii* YM.

**Quantification of pLDH units in different parasitized blood components**

It was then asked whether pLDH was limited to the red blood cell compartment or present both in the serum and pRBC. Blood samples obtained from mice infected with *P. chabaudi* AS and *P. yoelii* YM were separated into their components and the levels of pLDH units were determined in whole blood, serum and washed RBCs. Washed RBCs were prepared by washing whole blood thrice with PBS by centrifugation at 1500 rpm for 10 min. pLDH was detected in all three sample types, with whole blood showing higher levels of pLDH units compared to the serum and washed red blood cells (Fig. 2b).

**Sensitivity of the pLDH assay in mice infected with *Plasmodium chabaudi* AS and *Plasmodium berghei* ANKA**

*Plasmodium chabaudi* AS and *P. berghei* ANKA were selected for further studies. The limit of detection (LODs) were established by serially diluting whole parasitized
blood in naïve mouse blood. The LOD was approximately 0.7 % parasitaemia for *P. chabaudi* AS and 0.05 % for *P. berghei* ANKA (Fig. 3).

**Relationship between pLDH antigen levels and parasitaemia**

The correlation between levels of pLDH units and peripheral blood parasitaemias during the course of infection was then assessed. Blood was obtained from mice every day post onset of patent parasitaemia. To ensure that the *P. chabaudi*-infected mice were not anaemic and to allow collection of a suitable volume of blood, a large group of mice (n = 20) were infected and divided into two cohorts. Blood from each cohort was collected on alternate days. A strong correlation (r = 0.9889) was observed (Fig. 4).

**Relationship between pLDH units and total parasite bio‑burden in mice infected with Plasmodium berghei ANKA luciferase**

To evaluate the assay as a measure of total parasite bio-burden, BALB/c mice (n = 16) were infected with *P. berghei* ANKA luciferase and parasitized whole blood was collected every alternate day from eight mice post visualization under the bio-illuminator (see “Methods”) (Fig. 5). Total radiance (Fig. 6a) was determined for each mouse throughout the infection. The concentration of pLDH units and parasitaemia were also determined (Fig. 6b, c). No correlation (r = 0.2445) was observed between parasitaemia and pLDH units (Fig. 6d). However, a strong correlation (r = 0.6922) was observed between the levels of pLDH units and log average radiance (Fig. 6e).

**Discussion**

Current methods for the quantification of parasite levels in blood include microscopy, qPCR and flow cytometry, which are limited to detecting circulating parasites. These assays can be expensive and are unable to quantify total parasite bio-burden. Sequestration of parasites in the cerebral regions, placenta and bone marrow leads to an underestimation of total parasite bio-burden when using these assays [47–49]. This study demonstrated that pLDH units correlate with total parasite bio-burden in murine malaria models. A human *Plasmodium* antibody-based assay was used to quantify levels of pLDH in mice infected with different murine *Plasmodium*, including species that sequester in peripheral tissues or spleen, and established this assay as a measure of total parasite bio‑burden.

This study investigated the use of a commercial human malaria ELISA kit to detect levels of pLDH units in the blood and serum of infected mice. Some differences are observed between *P. falciparum* and rodent malaria LDH sequences (see above); therefore, pLDH ‘units’ rather than amount of pLDH per se has been referred to when assessing rodent parasites, with one unit being defined as
the OD equivalent of 1 ng of *Pf* LDH. pLDH units were detected at lower levels in *P. vinckei*-infected blood compared to mice infected with other parasites. The assay was more sensitive for *P. berghei* ANKA, which could be due to less sequence variation in the region of the antibody-binding site compared to other parasites. However, as the binding site of the antibody is currently unknown, this could not be confirmed.

This study compared the levels of pLDH units to an established bio-burden assay with luciferase transgenic parasites [8, 13] to establish an economical, high throughput in vivo parasite bio-burden assay that is not reliant on the use of luminescent parasites or expensive equipment. A strong correlation was observed between the bio-luminescence and pLDH assays. It was of interest that a strong correlation between *P. berghei* peripheral parasitaemia and pLDH levels was not detected, which may be due to the presence of sequestered parasites as shown in the bio-luminescent images (Fig. 5). The strong correlation that was observed between *P. chabaudi* peripheral parasitaemia and pLDH levels (Fig. 4c) likely reflects the fact that this parasite is highly synchronous and blood samples were taken in the morning when the parasites are at the ring stage and in the periphery.
Conclusions
This study demonstrates the use of an established human malaria pLDH kit for detecting murine malaria parasite bio-burden. pLDH was detected in four strains of murine *Plasmodium*. This assay permitted the estimation of pLDH in different components of infected blood, thus, accounting for both circulating and sequestered parasites. This is confirmed by the strong correlation between the bio-luminescence and pLDH units during the initial parasite growth. Therefore, this assay provides an accurate assessment of parasite bio-burden in rodent malaria species. Furthermore, these results suggest that the pLDH assay can provide a valid estimate of total parasite bio-burden in malaria-infected patients.

Fig. 5 Visualization of luciferase-expressing *Plasmodium berghei* ANKA parasites in representative BALB/c mice. The distribution of parasites was visualized by measuring luciferase activity in animals by using an I-CCD video camera. Rainbow images show the relative level of luciferase activity ranging from low (blue), to medium (green), to high (yellow, red). The scale of total photon counts can be different between separate illustrations. The white arrows indicate a naïve mouse.
Fig. 6 Relationship between pLDH units and total parasite bio-burden in mice (n = 16) infected with Plasmodium berghei ANKA luciferase. a Bio-luminescence measured as average radiance [p/s/cm²/sr] plotted on a logarithmic scale vs days post infection. b Mean concentration of pLDH units in whole blood obtained from infected mice days post infection. c Mean peripheral blood parasitaemia curves in infected mice as determined by microscopy. d Correlation between the pLDH units and mean parasitaemia, showing the coefficient correlation ($r = 0.2445$). e Correlation between the pLDH units and log average radiance, showing the coefficient correlation ($r = 0.6922$). Error bars represent mean ± SE of biological replicates. At day 1, the OD values for the infected mice were less than the control (naïve mouse blood).
Authors' contributions
All authors contributed to the design of this study and/or participated in experimental work, collection and analysis of data and/or the interpretation of the results, and to the writing of the manuscript. All authors edited the final version of the manuscript. All authors read and approved the final manuscript.

Author details
1 Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia.
2 QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Acknowledgements
This work was supported and funded by Griffith University and National Health and Medical Research Council (NHMRC, Australia). We thank Dr. Stephanie Yanow for reviewing the manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 4 September 2015 Accepted: 2 December 2015
Published online: 04 January 2016

References
1. WHO. World malaria report 2014. Geneva: World Health Organization; 2014. p. 242.
2. Baird JK, Owusu Agyei S, Utz GC, Koram K, Jones TR, et al. Seasonal malaria attack rates in infants and young children in northern Ghana. Am J Trop Med Hyg. 2002;66:280–6.
3. Giemsa G, Werner A. Erfahrungen mit weiteren dem Chinin nahestehenden Alkaloiden und einigen ihrer Derivate bei Malaria (Chinidin, Hydrochinidin, Cinchonin, Hydrocinchonin, Cuprein, ChinSthylin und Chinpropylin). Archiv für Schiffs- und Tropenygiene. 1914;18:12–5.
4. Fleischer B. Editorial: 100 years ago: Giemsa’s solution for staining of Plasmodia. Trop Med Int Health. 2004;9:755–6.
5. Jarra W, Snounou G. Only viable parasites are detected by PCR following clearance of rodent malarial infections by drug treatment or immune responses. Infect Immun. 1998;66:3783–7.
6. Grimbong BT. Methodology and application of flow cytometry for investigation of human malaria parasites. J Immunol Meth. 2011;361:1–16.
7. Shapiro HM, Apte SH, Chojnowski GM, Hanscheid T, Rebelo M, Grimberg BT. Cytometry in malaria—a practical replacement for microscopy? Curr Protoc in Cytom. 2013;65:11.20.11–11.20.23.
8. Franke-Fayard B, Trueeman H, Ramesar J, Mendoza J, van der Keur M, van der Linden R, et al. A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol Biochem Parasitol. 2004;137:23–33.
9. Janse CJ, Franke-Fayard B, Mair GR, Ramesar J, Thiel C, Engelmann S, et al. High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol Biochem Parasitol. 2006;145:60–70.
10. Franke-Fayard B, Djokovic D, Dooren M, Ramesar J, Waters A, Falade M, et al. Simple and sensitive antimalarial drug screening in vitro and in vivo using transgenic luciferase expressing Plasmodium berghei parasites. Int J Parasitol. 2008;38:1651–62.
11. Pappas M. Chromium labelling of erythrocytes and their application in clearance and sequestration during malaria. In: Hayunga E, Stek MJ, editors. Nuclear and related techniques in parasitology. Vienna: International Atomic Energy Agency (IAEA); 1986. p. 89.
12. Mallaret B, Claser C, Ong ASM, Suwanarsirikul S, Riprawat K, Howland SW, et al. A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development. Sci Rep. 2011;1:118.
13. Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, Ramesar J, Buescher P, Que I, et al. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci USA. 2005;102:11468–73.
14. Franke-Fayard B, Waters AP, Janse CJ. Real-time in vivo imaging of transgenic bioluminescent blood stages of rodent malaria parasites in mice. Nat Protoc. 2006;1:476–85.
15. Fonager J, Pasini EM, Braks JA, Klop O, Ramesar J, Remarque EJ, et al. Reduced CD36-dependent tissue sequestration of Plasmodium-infected erythrocytes is detrimental to malaria parasite growth in vivo. J Exp Med. 2012;209:993–107.
16. Claser C, Mallaret B, Gun SY, Wong AW, Chang ZW, Teo P, et al. CD8+ T cells and IFN-gamma mediate the time-dependent accumulation of infected red blood cells in deep organs during experimental cerebral malaria. PLoS One. 2011;6:e18720.
17. Piper RC, Vanderjagt DL, Holbrook JJ, Makler M. Malaria lactate dehydrogenase: target for diagnosis and drug development. Ann Trop Med Parasitol. 1996;90:433.
18. Odoula AM, Omitowoju GO, Sowunmi A, Makler MT, Falade CO, Kyle DE, et al. Plasmodium falciparum: evaluation of lactate dehydrogenase in monitoring therapeutic responses to standard antimalarial drugs in Nigeria. Exp Parasitol. 1997;87:283–9.
19. Palmer CJ, Lindo JD, Klasiska W, Quesada JA, Kaminsky R, Baum MK, et al. Evaluation of the OptiMAL test for rapid diagnosis of Plasmodium vivax and Plasmodium falciparum malaria. J Clin Microbiol. 1998;36:203–6.
20. Makler MT, Piper RC, Milhous WK. Lactate dehydrogenase and the diagnosis of malaria. Parasitol Today. 1998;14:376–7.
21. Cooke A, Chiordini P, Doherty T, Moody A, Ries J, Pinder M. Comparison of a parasite lactate dehydrogenase-based immunochromatographic antigen detection assay (OptiMAL) with microscopy for the detection of malaria parasites in human blood samples. Am J Trop Med Hyg. 1999;60:173–6.
22. Moody AH, Chiordini PL. Non-microscopic method for malaria diagnosis using OptiMAL IT, a second-generation dipstick for malaria pLDH antigen detection. Br J Biomed Sci. 2002;59:228–31.
23. WHO, FIND, CDC, TDR. Malaria rapid diagnostic test performance: results of WHO product testingmalaria RDTs round 2 (2009). NLM Classification: WC. 750. 2010. pp. 1–22. ISBN 9789241599467
24. Hendriksen IC, Motev G, Pedro AJ, Gomes E, Silamut K, Lee SJ, Mwambuli A, et al. Evaluation of a PHRP2 and a pLDH-based rapid diagnostic test for the diagnosis of severe malaria in 2 populations of African children. Clin Infect Dis. 2011;52:1100–7.
25. Beadle C, Long GW, McElroy PD, Hoffman SL, Long GW, Weiss WR, et al. Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet. 1994;343:564–8.
26. Makler MT, Hinrichs DJ. Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. Am J Trop Med Hyg. 1993;48:205–10.
27. Jelinek T, Kilian AH, Henk M, Mughusu BE, Nothdurft HD, Loscher T, et al. Parasite-specific lactate dehydrogenase for the diagnosis of Plasmodium falciparum infection in an endemic area in west Uganda. Trop Med Int Health. 1996;1:227–30.
28. Roussel K, Lebras J, Wentworth L, Hunt-Cookie A, Houze S, Chiordini P, et al. Immunoaustrophage assays for malaria using Plasmodium lactate dehydrogenase (pLDH). Am J Trop Med Hyg. 1999;60:19–18.
29. Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev. 2002;15:66–78.
30. Mariette N, Barnadas C, Bouchier C, Tichit M, Menard D. Country-wide assessment of the genetic polymorphism in Plasmodium falciparum. BMC Biol. 2013;11:67.
31. MacRae JI, Dixon MWA, Dearnley MK, Chua HH, Chambers JM, Kenny SM. Mitochondrial metabolism of sexual and asexual blood stages of the malaria parasite Plasmodium falciparum. BMC Biol. 2013;11:67.
32. Lang-Unnasch N, Murphy AD. Metabolic changes of the malaria parasite during the transition from the human to the mosquito host. Annu Rev Microbiol. 1998;52:561–90.
33. Brown W, Yowell C, Hoard A, Vander Jagt T, Hunsaker L, Deck L, et al. Comparative structural analysis and kinetic properties of lactate dehydrogenases from the four species of human malarial parasites. Biochemistry. 2004;43:6219–29.
34. Howard RJ, Uni S, Aikawa M, Aley SB, Leech JH, Lew AM, et al. Secretion of a malarial histidine-rich protein (PHHRP2) from Plasmodium falciparum-infected erythrocytes. J Cell Biol. 1986;103:1269–77.
35. Koita OA, Doumbou OK, Ouattara A, Tall LK, Konaré A, Diakité M, et al. False-negative rapid diagnostic tests for malaria and deletion of the histidine-repeat region of the hps2 gene. Am J Trop Med Hyg. 2012;86:194–8.
36. Fogg C, Twesigye R, Batwala V, Piola P, Naserumba C, Kiguli J, et al. Assessment of three new parasite lactate dehydrogenase (pan-pLDH)
tests for diagnosis of uncomplicated malaria. Trans R Soc Trop Med Hyg. 2008;102:25–31.

37. Gersl S, Dunkley S, Mukhtar A, De Smet M, Baker S, Maikere J. Assessment of two malaria rapid diagnostic tests in children under five years of age, with follow-up of false-positive pLDH test results, in a hyperendemic falciparum malaria area, Sierra Leone. Malar J. 2010;9:28.

38. Dien T, Bah I, Ndiaye PM, Diallo I, Diop BM, Basseur P, et al. In vitro evaluation of the sensitivity of Plasmodium falciparum to chloroquine using the deli-microtest in region of Dakar, Senegal. Med Trop (Mars). 2005;65:580–3.

39. Atchade PS, Doderer-Lang C, Chabi N, Perrotey S, Abdelrahman T, et al. Is a Plasmodium lactate dehydrogenase (pLDH) enzyme-linked immuno-sorbent (ELISA)-based assay a valid tool for detecting risky malaria blood donations in Africa? Malar J. 2013;12:279.

40. Orjuela-Sanchez P, Duggan E, Nolan J, Frangos J, Carvalho L. A lactate dehydrogenase ELISA-based assay for the in vitro determination of Plasmodium berghei sensitivity to anti-malarial drugs. Malar J. 2012;11:366.

41. Otsuki H, Yokouchi Y, Iyoku N, Tachibana M, Tsuboi T, Torii M. The rodent malaria lactate dehydrogenase assay provides a high throughput solution for in vivo vaccine studies. Parasitol Int. 2015;64:60–3.

42. Turgut-Balik D, Akbulut E, Shoemark DK, Celik V, Moreton KM, Sessions RB, et al. Cloning, sequence and expression of the lactate dehydrogenase gene from the human malaria parasite, Plasmodium vivax. Biotechnol Lett. 2004;26:1051–5.

43. Mayxay M, Pukrittayakamee S, Newton PN, White NJ. Mixed-species malaria infections in humans. Trends Parasitol. 2004;20:233–40.

44. Hurdayal R, Achilonu I, Choveaux D, Coetzter T, Dean Goldring J. Antipeptide antibodies differentiate between plasmodial lactate dehydrogenases. Peptides. 2010;31:525–32.

45. Talman AM, Duval L, Legrand E, Hubert V, Yen S, Bell D, et al. Evaluation of the intra- and inter-specific genetic variability of Plasmodium lactate dehydrogenase. Malar J. 2007;6:140.

46. National Health and Medical Research. Australian code for the care and use of animals for scientific purposes. 8th edn. Canberra: National Health and Medical Research Council; 2013.

47. Hearn J, Rayment N, Landon DN, Katz DR, de Souza JB. Immunopathology of cerebral malaria: morphological evidence of parasite sequestration in murine brain microvasculature. Infect Immun. 2000;68:5364–76.

48. Gonçalves BP, Huang C-Y, Morrison R, Holte S, Kabyemela E, Prevots R, et al. Parasite burden and severity of malaria in Tanzanian Children. N Engl J Med. 2014;370:799–808.

49. Joice R, Nilsson SK, Montgomery J, Dankwa S, Egan E, Morahan B, et al. Plasmodium falciparum transmission stages accumulate in the human bone marrow. Sci Transl Med. 2014;6:244re245.